Epithelial ovarian cancer (EOC) is the leading cause of death due to gynecologic malignancy. The majority of advanced stage EOC patients, even those who respond well to frontline therapy, will ultimately recur and succumb to their disease. In platinum-sensitive EOC patients, or those who recur ≥6 months from initial diagnosis, treatment of recurrent disease has traditionally consisted of repeat platinum-based chemotherapy. Secondary cytoreduction remains controversial. Due to recent advances in molecularly targeted treatment options, outcomes for advanced stage EOC patients are significantly improving and hold great promise. This review discusses pivotal trials establishing platinum-based combination chemotherapy as the standard of care and addresses the utility of increasing a patient's platinum-free interval. It then discusses the role of anti-angiogenesis therapeutics, specifically bevacizumab, cediranib, and trebananib and their side effects. Lastly, it reviews key trials for the three poly-adenosine diphosphate [ADP]-ribose polymerases (PARP) inhibitors that have been FDA-approved for maintenance therapy in platinum-sensitive recurrent EOC: olaparib, rucaparib, and niraparib. This review concludes with a discussion regarding ongoing and future clinical trials.

Original languageEnglish
Pages (from-to)416-425
Number of pages10
JournalGynecologic oncology
Issue number2
StatePublished - Feb 2019


  • Anti-angiogenesis
  • Bevacizumab
  • PARP inhibitors
  • Platinum-sensitive
  • Recurrent ovarian cancer
  • Targeted therapy


Dive into the research topics of 'Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review'. Together they form a unique fingerprint.

Cite this